Catalent joins the EuropaBio 25th Anniversary in 2021
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
Showing Results 121-130 Of 76 For Italy
Catalent Appoints Corporate Development and Science Leaders to Drive Growth and Innovation
Catalent today announced it has appointed Mike Grippo as Senior Vice President, Strategy and Corporate Development. Alongside his appointment, Julien Meissonnier has been named as Vice President and Chief Scientific Officer, and will report to Mr. Grippo.
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
Catalent today announced a collaboration with Johnson & Johnson for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.
Catalent Biologics Completes $14 Million Commercial Packaging Expansion at its Bloomington, Indiana Facility
Catalent today announced the completion of its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility.
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.